

図5 インターフェロン投与別のC型肝硬変発癌率。(インターフェロン投与群は投与開始を観察開始とした)

(Cox 比例ハザードモデル)の結果では、発癌を有意に高める要因は低アルブミン血症、男性、高齢、HCV サブタイプ1または200kg以上の飲酒歴、高AFP血症、低血小板血症であった²⁾。さらに、インターフェロンによる医療介入を加えた解析では、ICG15分値とインターフェロン投与も発癌率に寄与する独立要因であった。インターフェロン投与群は非投与群と比較して有意に発癌率が低く(図5)、多変量解析でのハザード比はウイルス排除例+生化学的著効例で0.35、継続投与群で0.47であった。またインターフェロン投与群では生存率も有意に改善された。

考 察

1998年の調査と同様に当科の特徴はB型が他施設よりも多いことである。これは地域的な特徴に加えて当施設において1980年代にB型慢性肝炎症例の受診例が多く、その症例が肝硬変へと進展していることも一因である。NASHは1.1%と少数ではあったが、時代とともに増加傾向を示している。NASH肝硬変の場合には発癌を機に発見されることが多く、本報告で除外した肝硬変診断時にすでに肝癌を合併している例を加えると、NASH肝硬変の割合はより高率であることが予想される。

男女比を1990年代と比較すると、C型肝硬変では0.56→0.72と女性の比率の増加がみられ

る。とくに2000年以降にC型肝硬変と初めて診断された例は男女比1:1.05と男女ほぼ同数であった。C型肝硬変以外の成因例では、男女比は1990年代とほぼ同じであった。

肝硬変患者の年齢中央値は徐々に上昇しており高齢化が明らかである。この原因としては、慢性肝炎に対するインターフェロンや核酸アナログなどによる治療が普及し、肝線維化の進行が抑制されていること、肝硬変に対するインターフェロンあるいは核酸アナログによる治療により発癌が抑制されていること、肝癌のコントロールが改善していることなどが考えられる。以前より肝硬変の死因としては癌死が最も多いが、1998年の報告と比較するとB型の癌死は50%→53%、C型は56→65%とともにさらに増加しており、発癌予防の重要性がさらに増している。当院ではB型肝硬変への核酸アナログ投与、C型肝硬変へのインターフェロン投与が以前から試みられており、発癌率、生存率ともに改善するという傾向が認められているが、その結果を確かめるためにさらなる経過観察が必要と考える。

文献

- 1) 斉藤 聡, 池田健次, 熊田博光: 肝硬変の成因別実態。「肝硬変の成因別実態」1998, 21-25.
- 2) 池田健次, 熊田博光: B, C型肝癌の背景。「ウイルス性肝炎からの発癌とその予防」2005,

Substitution of Amino Acid 70 in the Hepatitis C Virus Core Region of Genotype 1b Is an Important Predictor of Elevated Alpha-Fetoprotein in Patients Without Hepatocellular Carcinoma

Norio Akuta,^{1*} Fumitaka Suzuki,¹ Yusuke Kawamura,¹ Hiromi Yatsuji,¹ Hitomi Sezaki,¹ Yoshiyuki Suzuki,¹ Tetsuya Hosaka,¹ Masahiro Kobayashi,¹ Mariko Kobayashi,² Yasuji Arase,¹ Kenji Ikeda,¹ and Hiromitsu Kumada¹

¹Department of Hepatology, Toranomon Hospital, Tokyo, Japan

²Liver Research Laboratory, Toranomon Hospital, Tokyo, Japan

Previous studies identified amino acid (aa) substitutions of the hepatitis C virus core region of genotype 1b (HCV-1b core region) and elevated serum alpha-fetoprotein (AFP) levels as predictors of poor virologic response to pegylated interferon (PEG-IFN) plus ribavirin (RBV), and also as risk factors for hepatocarcinogenesis. The present study evaluated the impact of aa substitutions of HCV-1b core region on AFP, as a surrogate marker of hepatocarcinogenesis, on AFP levels in 569 Japanese patients with HCV-1b but without HCC, and investigated the predictive factors of elevated AFP ($\geq 11 \mu\text{g/L}$). High AFP levels were detected in 27.4% of the patients. The rate of hepatocarcinogenesis in a group of 109 patients who received IFN monotherapy and followed-up for 15 years, was significantly higher in patients with abnormal than normal AFP. Multivariate analysis of 569 patients identified fibrosis stage (F3,4), aspartate aminotransferase ($\geq 76 \text{ IU/L}$), substitution of aa 70 (glutamine or histidine), and platelet count ($< 15.0 \times 10^4/\mu\text{l}$) as significant determinants of elevated AFP. In 49 patients with abnormal AFP levels and substitutions at aa 70 who were treated with PEG-IFN + RBV, the rate of normalization of AFP was significantly lower in non-virological responders (28.6%) than in transient (71.4%) and sustained (100%) virological responders. The results indicated that substitution of aa 70 of HCV-1b core region is an important predictor of elevated AFP in non-HCC patients, and that eradication of the mutant virus normalizes AFP. The results highlight the importance of eradication of mutant type virus of aa 70 for reducing the risk of hepatocarcinogenesis.

J. Med. Virol. 80:1354–1362, 2008.

© 2008 Wiley-Liss, Inc.

KEY WORDS: HCV; core region; genotype; AFP; hepatocellular carcinoma; glutamine; histidine

INTRODUCTION

Hepatitis C virus (HCV) usually causes chronic infection that can result in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) [Dush-eiko, 1998; Ikeda et al., 1998; Niederau et al., 1998; Kenny-Walsh, 1999; Akuta et al., 2001]. In patients with HCV-chronic hepatitis, treatment with interferon (IFN) can induce viral clearance and marked biochemical and histological improvement [Davis et al., 1989; Di Bisceglie et al., 1989]. Especially, pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy can achieve a high sustained virological response, although patients with non-virological response who remain HCV-RNA-positive at the completion of treatment are also encountered [Akuta et al., 2005, 2006, 2007a,b,c]. Previous studies indicated that amino acid (aa) substitutions at position 70 and/or 91 in the HCV core region of genotype 1b (HCV-1b core region) and elevated alpha-fetoprotein (AFP) levels were predictors of poor virological response to PEG-IFN plus RBV therapy [Akuta et al., 2005, 2006, 2007a,b,c; Donlin et al., 2007], and also risk factors and surrogate markers of hepatocarcinogenesis [Ikeda et al., 2006; Akuta et al., 2007d].

*Correspondence to: Norio Akuta, MD, Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-0001, Japan. E-mail: akuta-gi@umin.ac.jp

Accepted 11 March 2008

DOI 10.1002/jmv.21202

Published online in Wiley InterScience
(www.interscience.wiley.com)

The use of elevated AFP as a predictor of early hepatocarcinogenesis in non-HCC patients might be clinically useful. AFP is a fetal glycoprotein produced by the yolk sac and fetal liver [Bergstrand and Czar, 1956], and has been used widely as a serum marker for the diagnosis of HCC [Sato et al., 1993; Johnson, 2001]. Furthermore, elevated serum AFP is also associated with various chronic liver diseases and hepatic regeneration [Kew et al., 1973; Silver et al., 1974; Elftherious et al., 1977; Alpert and Feller, 1978]. Although a mild rise in serum AFP is commonly seen in chronic HCV-infected patients, its clinicopathological significance remains to be defined. Previous studies indicated that high serum AFP levels correlated with fibrosis stages 3 and 4 [Bayati et al., 1998; Chu et al., 2001; Hu et al., 2002, 2004], levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) [Chu et al., 2001; Stein and Myaing, 2002; Hu et al., 2004], prothrombin time [Hu et al., 2004], and HCV-1b [Chu et al., 2001], in chronic HCV-infected patients. However, it is not clear whether mild elevation of AFP in the absence of HCC is associated with eventual development of HCC in HCV-infected patients. Furthermore, the impact of viral factors, such as aa substitutions of HCV-1b core region, on elevated AFP is still unclear.

The aims of the present study conducted in HCC-free Japanese patients infected with HCV-1b, were the following. (1) To evaluate the impact of elevated AFP, especially mild elevation of AFP, on hepatocarcinogenesis in IFN-treated patients without HCC during a long-term (15 years) follow-up period. (2) To identify the impact of aa substitutions in the core region on AFP levels in such patients, and determine the predictive factors for elevated AFP. (3) To investigate the normalization rates of AFP levels after eradication of HCV-RNA by PEG-IFN plus RBV combination therapy.

PATIENTS AND METHODS

Study Population

At Toranomon Hospital, Tokyo, Japan, 2,841 HCV-infected Japanese patients were recruited consecutively into the study protocol of IFN monotherapy between February 1987 and August 2007, and 929 HCV-infected Japanese patients were consecutively recruited into the study protocol of the combination therapy with PEG-IFN α -2b plus RBV between December 2001 and August 2007. Among these, 569 patients were selected in the present retrospective study based on the following criteria. (1) They were negative for hepatitis B surface antigen (radioimmunoassay, Dainabot, Tokyo), positive for anti-HCV (third-generation enzyme immunoassay, Chiron Corp., Emerville, CA), and positive for HCV-RNA qualitative analysis with PCR (nested PCR or AmplicorTM, Roche Diagnostics, Indianapolis, IN). (2) They were naive to antiviral treatment. (3) They were infected with HCV-1b alone. (4) AFP levels were measured frequently, and substitutions of aa 70 or 91 in the HCV core region (HCV mutant-70 and HCV mutant-91, respectively) were determined at the commencement

of the first course of antiviral treatment. (5) They were free of HCC based on clinical examination, laboratory tests, and imaging studies at baseline. (6) None was an alcoholic; lifetime cumulative alcohol intake was <500 kg (mild to moderate alcohol intake). (7) All were free of coinfection with human immunodeficiency virus. (8) None had other forms of hepatitis, such as hemochromatosis, Wilson disease, primary biliary cirrhosis, alcoholic liver disease, and autoimmune liver disease. (9) Each signed a consent form of the study protocol that had been approved by the Human Ethics Review Committee of Toranomon Hospital. Table I summarizes the profiles and laboratory data of the 569 patients at the commencement of antiviral treatment. They included 347 males and 222 females, aged 18–77 years (median, 55 years). Of the total group of 569 patients, 229 received IFN monotherapy, while 340 were treated with PEG-IFN plus RBV combination therapy. Among the patients who received IFN monotherapy, 109 patients started the monotherapy between February 1987 and August 1992, received at least two courses of such therapy, and were followed-up for 15 years. They were evaluated for the rate of development of HCC, associated with a rise in AFP level relative to that measured before the first course IFN monotherapy (baseline). At baseline, the latter group consisted of 80 males and 29 females, aged 22–69 with a median age of 46 years. The numbers of patients with fibrosis stages 1, 2, 3, and 4 were 57, 37, 14, and 1, respectively. The median AST and ALT levels were 85 IU/L (range, 27–400 IU/L) and 138 IU/L (range, 50–594 IU/L), respectively. The median platelet count was $17.0 \times 10^4/\mu\text{l}$ (range, 9.8×10^4 to $31.2 \times 10^4/\mu\text{l}$). The median viremia level was 5.8 Mequiv./ml (range, <0.5–46.5 Mequiv./ml). The median AFP level was 5 $\mu\text{g/L}$ (range, 2–239 $\mu\text{g/L}$). The median follow-up time was 16.0 years (range, 0.1–20.3 years). With regard to

TABLE I. Profile and Laboratory Data of 569 Patients Infected with HCV Genotype 1b

Number of patients	569
Sex (male/female)	347/222
Age (years)*	55 (18–77)
Serum aspartate aminotransferase (IU/L)*	59 (17–400)
Serum alanine aminotransferase (IU/L)*	84 (15–594)
Platelet count ($\times 10^4/\mu\text{l}$)*	16.1 (3.8–40.2)
Serum alpha-fetoprotein ($\mu\text{g/L}$)*	6 (2–459)
Fibrosis stage (F1/F2/F3/F4/ND)	227/132/76/17/117
Level of viremia (high titer/low titer)**	522/47
Amino acid substitutions in core region***	
aa 70 (wild/mutant)	340/229
aa 91 (wild/mutant)	341/228
Treatment	
IFN monotherapy/PEG-IFN plus RBV	229/340

Data are number of patients, except those denoted by *, which represent the median (range) values. (**) Level of viremia was evaluated as high titer (≥ 1.0 Meq/ml, or ≥ 100 KIU/ml) and low titer (<1.0 Meq/ml, or <100 KIU/ml). (***) The presence of arginine at aa 70 was evaluated as wild type, while other patterns (glutamine/histidine) as mutant type. The presence of leucine at aa 91 was evaluated as wild type, while other patterns (methionine) as mutant type. Normal reference ranges: 11–38 IU/L for aspartate aminotransferase; 6–50 IU/L for alanine aminotransferase (IU/L); ≤ 10 $\mu\text{g/L}$ for alpha-fetoprotein. ND: not done; IFN: interferon; PEG-IFN: pegylated interferon; RBV: ribavirin.

the protocol of IFN monotherapy, 68 (62.4%) patients received IFN- α alone; 36 (33.0%) patients received IFN- β alone; while the remaining 5 (4.6%) patients received a combination of IFN- α and IFN- β . The median IFN dose per day of 6 million units (MU, range; 1–10 MU) was administered. IFN monotherapy included initial aggressive induction therapy, consisting of every day within the first 8 weeks of commencement of therapy, followed subsequently by three times per week.

On the other hand, 340 patients received PEG-IFN α -2b combination therapy at a median dose of 1.5 μ g/kg (range, 0.8–1.8 μ g/kg) subcutaneously each week plus oral RBV at a median dose of 11.0 mg/kg (range, 3.4–14.2 mg/kg) daily for a median duration of 48 weeks (range, 9–112 weeks).

In this study, patients who were HCV-RNA-negative by qualitative PCR analysis at 24 weeks after the completion of therapy, were defined as sustained virological responders. On the other hand, patients who were HCV-RNA-negative by qualitative PCR analysis at the completion of 24-week treatment but became HCV-RNA-positive after the 24-week therapy, were defined as transient virological responders. Patients who remained HCV-RNA-positive by quantitative and/or qualitative PCR analyses at the completion and after treatment, were defined as non-virological responders.

Laboratory Investigations

Blood samples were obtained at least once every month before, during, and after treatment, and were analyzed for AST, ALT, and HCV-RNA levels. The serum samples were frozen at -80°C within 4 hr of collection and then thawed at the time of measurement. HCV genotype was determined by PCR using a mixed primer set derived from nucleotide sequences of NS5 region [Chayama et al., 1993]. HCV-RNA levels were measured by branched DNA assay version 2.0 (Chiron Corp., Emeryville, CA) or quantitative PCR assay (Cobas Amplicor HCV monitor v 2.0 using the 10-fold dilution method, Roche) before, during, and after the antiviral therapy. The lower limits of these assays were 0.5 Meq/ml (10^6 genomic equivalents per milliliter) by branched DNA assay, or 5 KIU/ml by quantitative PCR assay. Samples with undetectable levels by these quantitative assays (<0.5 Meq/ml, or <5 KIU/ml) were checked also by HCV-RNA qualitative analysis with PCR (nested PCR or AmplicorTM, Roche) during and after treatment especially, and the results were expressed as positive or negative. The lower limit of the assay was 50 IU/ml. In this study, levels of viremia were evaluated as high titer (≥ 1.0 Meq/ml, or ≥ 100 KIU/ml) and low titer (<1.0 Meq/ml, or <100 KIU/ml).

Histopathological Examination of Liver Biopsies

Liver biopsy specimens were obtained percutaneously or at laparotomy using a modified Vim Silverman needle with an internal diameter of 2 mm (Tohoku

University style, Kakinuma Factory, Tokyo). The biopsy material was fixed in 10% formalin, and stained with hematoxylin and eosin, Masson's trichrome, silver impregnation, and periodic acid-Schiff after diastase digestion. All specimens for examination contained six or more portal areas. Histopathological diagnosis was confirmed by an experienced liver pathologist (H.K.) who was blinded to the clinical data. Chronic hepatitis and liver cirrhosis were diagnosed based on histological assessment according to the scoring system of Desmet et al. [1994].

Detection of Amino Acid Substitutions in Core Region

Okamoto et al. [2007] developed a simple PCR method for detecting substitutions of aa 70 or aa 91 in HCV-1b core region using mutation-specific primer, as an alternative to the direct sequencing method. The major protein type was determined based on the relative intensity of the bands for wild (aa 70: arginine, aa 91: leucine) and mutant HCV-1b (aa 70: glutamine/histidine, aa 91: methionine) in agarose gel electrophoresis. If the intensities of the bands were similar, the case was regarded as competitive. The detection rate was 94.4%, the sensitivity was 10 KIU/ml using quantitative assay with PCR (Cobas Amplicor HCV monitor v 2.0 using the 10-fold dilution method, Roche), the reproducibility was high, and consistency with direct sequencing was 97.1% in positive cases. Mutation in this study refers to substitution from consensus sequence. In previous studies, HCV-J (accession no. D90208) was considered a prototype and the aa substitution was evaluated by comparison with the consensus sequence prepared from 50 clinical trial samples [Kato et al., 1990; Akuta et al., 2005]. In the present study, PCR using primers specific for substitutions of aa 70 or aa 91 was performed in samples collected from 454 patients [Okamoto et al., 2007]; the remaining 115 patients were analyzed by direct sequencing [Akuta et al., 2005, 2006].

Diagnosis of Hepatocellular Carcinoma

Patients were examined for HCC by abdominal ultrasonography every 3–6 months. If HCC was suspected based on ultrasonographic results, additional procedures, such as computed tomography, magnetic resonance imaging, abdominal angiography, and ultrasonography-guided tumor biopsy, were used to confirm the diagnosis.

Statistical Analysis

Non-parametric tests were used to compare variables between groups, including the Mann-Whitney *U*-test, chi-squared test and Fisher's exact probability test. Multiple comparisons were conducted by the Bonferroni test. The cumulative rate of hepatocarcinogenesis was calculated using the Kaplan-Meier technique; differences between carcinogenesis curves between groups were tested using the log-rank test. Statistical analyses of the rate of hepatocarcinogenesis according to

groups were calculated using the period from start of the first course of IFN monotherapy. Univariate and multivariate logistic regression analyses were used to determine the independent predictive factors of elevated AFP. The odds ratios and 95% confidence intervals (95% CI) were also calculated. All *P* values less than 0.05 by the two-tailed test were considered significant. Variables that achieved statistical significance ($P < 0.05$) or marginal significance ($P < 0.10$) on univariate analysis were entered into multiple logistic regression analysis to identify significant independent factors. Potential predictive factors associated with elevated AFP included the following pretreatment variables: sex, age, AST, ALT, platelets, pathological staging, viremia level, and aa substitutions in the core region. Statistical analyses were performed using the SPSS software (SPSS Inc., Chicago, IL).

RESULTS

Cumulative Rate of Hepatocarcinogenesis According to AFP Levels

Of the 229 patients who received IFN monotherapy, 109 could be evaluated for the rate of development of HCC based on AFP levels measured at the start of the first course IFN monotherapy (baseline), during a follow-up period of 15 years. All 109 patients received two or more courses of IFN monotherapy; 66 patients received two courses of IFN (including 16 patients who achieved sustained virological response), 35 patients received three courses (including 4 patients who achieved sustained virological response), 7 patients received four courses (including 1 patient who achieved sustained virological response), and one patient received six courses (did not achieve sustained virological response). Thus, 21 of 109 patients achieved sustained virological response after multicourses of IFN monotherapy. For those who received 1, 2, 3, 4, 5, and 6 courses of IFN monotherapy, the median total duration of IFN therapy was 23.9 weeks (range, 0.9–134.7 weeks), 24.0 (range, 1.3–313.7), 25.1 (range, 3.1–193.1), 40.3 (range, 21.0–86.3), 23.6, and 67.9, respectively, and the median total dose of IFN was 526 MU (range, 22–1393 MU), 589 (range, 57–4005), 501 (range, 28–3477), 536 (range, 363–1553), 708, and 1200, respectively. The median cumulative total duration and cumulative total dose, which represented the cumulative total duration and total dose of every course of every patient were 57.7 weeks (range, 14.0–467.6 weeks) and 1380 MU (range, 521–4805 MU), respectively. The median period during which no IFN was administered was 3.7 years (range, 0.1–7.0 years). Finally, the median dose of IFN per week was 22.5 MU (range, 3.7–43.9).

During the follow-up, 8.6% (7 of 81 patients), 20.0% (3 of 15), and 38.5% (5 of 13) developed HCC in patients with AFP levels below 1 (≤ 10 $\mu\text{g/L}$), from 1 to 2 (11–20 $\mu\text{g/L}$), and above twice (≥ 21 $\mu\text{g/L}$) the upper limit of normal (ULN), respectively. In patients with AFP levels below 1, from 1 to 2, and above 2 times the ULN, the

cumulative hepatocarcinogenesis rates were 0, 7.1, 0% at the end of 5 years; 3.1, 23.4, 37.5% at the end of 10 years; and 14.5, 23.4, 58.3% at the end of 15 years, respectively. The rates were significantly different among the three groups ($P < 0.001$; log-rank test) (Fig. 1). Especially, the rate of hepatocarcinogenesis in patients with normal AFP levels was significantly lower than in those with AFP levels above twice ULN ($P < 0.001$), and tended to be lower than in those with AFP levels from 1 to 2 times ULN ($P = 0.070$). The rate of hepatocarcinogenesis in patients with AFP levels above twice ULN was not significantly higher than in those with AFP levels from 1 to 2 times ULN. Thus, the rate of hepatocarcinogenesis was significantly higher in patients with abnormal AFP levels than in those with normal AFP levels ($P < 0.001$).

Predictive Factors of Elevated AFP in Univariate and Multivariate Analyses

The virological, clinical, and biochemical features of the whole population sample of 569 patients were analyzed to determine factors that could predict elevated AFP (≥ 11 $\mu\text{g/L}$). Elevated AFP was detected in 156 of 569 (27.4%) patients. Univariate analysis identified seven parameters that influenced significantly high AFP level. These included age (≥ 45 years, $P = 0.001$), AST (≥ 76 IU/L, $P < 0.001$), ALT (≥ 100 IU/L, $P < 0.001$), platelets ($< 15.0 \times 10^4/\mu\text{l}$, $P < 0.001$), stage of fibrosis (F3,4, $P < 0.001$), and aa substitutions of the core region (mutant type of aa 70, $P < 0.001$, and aa 91, $P = 0.035$). Multivariate analysis identified four parameters that independently influenced high AFP level, including stage of fibrosis (F3,4, $P < 0.001$), AST (≥ 76 IU/L, $P < 0.001$), substitution of aa 70 (mutant type, $P < 0.001$), and platelet count ($< 15.0 \times 10^4/\mu\text{l}$, $P = 0.019$) (Table IIA).




Fig. 1. Cumulative rate of hepatocarcinogenesis according to AFP levels at the start of first course IFN monotherapy. The rate of hepatocarcinogenesis in patients with normal AFP levels (≤ 10 $\mu\text{g/L}$) was significantly lower than in those with AFP levels above twice the upper limit of normal (≥ 21 $\mu\text{g/L}$) ($P < 0.001$), and tended to be lower than in those with AFP levels from 1 to 2 times the upper limit of normal (11–20 $\mu\text{g/L}$) ($P = 0.070$). The rate of hepatocarcinogenesis in patients with abnormal AFP levels (≥ 11 $\mu\text{g/L}$) was significantly higher than in those with normal AFP levels ($P < 0.001$).

TABLE IIA. Factors Associated with Elevated Serum AFP Levels (≥ 11 $\mu\text{g/L}$) in Patients Infected with HCV Genotype 1b, Identified by Multivariate Analysis

Factor	Category	Odds ratio (95% CI)	P
Fibrosis stage	1: F1,2	1	
	2: F3,4	5.014 (2.746–9.153)	<0.001
Aspartate aminotransferase (IU/L)	1: <76	1	
	2: ≥ 76	4.592 (2.707–7.789)	<0.001
Substitution of aa 70	1: wild type	1	
	2: mutant type	2.618 (1.561–4.391)	<0.001
Platelet count ($\times 10^4/\mu\text{l}$)	1: ≥ 15.0	1	
	2: <15.0	1.912 (1.111–3.289)	0.019

*The presence of arginine at aa 70 was evaluated as wild type, while other patterns (glutamine/histidine) as mutant type. Normal reference ranges: ≤ 10 $\mu\text{g/L}$ for alpha-fetoprotein.

The entire population sample was also analyzed to determine factors that could predict elevated AFP above twice ULN (≥ 21 $\mu\text{g/L}$); which was noted in 75 of 569 (13.2%) patients. Univariate analysis identified seven parameters that significantly influenced elevated AFP above twice ULN. These included age (≥ 45 years, $P = 0.015$), AST (≥ 76 IU/L, $P < 0.001$), ALT (≥ 100 IU/L, $P < 0.001$), platelet count ($< 15.0 \times 10^4/\mu\text{l}$, $P < 0.001$), stage of fibrosis (F3,4, $P < 0.001$), and aa substitutions of the core region (mutant type of aa 70, $P < 0.001$, and aa 91, $P = 0.008$). Multivariate analysis identified four parameters that influenced independently elevated AFP above twice ULN, including stage of fibrosis (F3,4, $P < 0.001$), AST (≥ 76 IU/L, $P < 0.001$), and aa substitutions of the core region (HCV mutant-91, $P = 0.029$, and -70, $P = 0.056$) (Table IIB).

AFP Levels and aa Substitutions of Core Region

The entire population sample was also analyzed to determine the relationship between aa substitutions of the core region and AFP levels. The proportions of patients with HCV mutant-70 among those with AFP levels below 1, from 1 to 2, from 2 to 4, from 4 to 8, and above 8 times ULN were 33.4% (138 of 413 patients), 53.1% (43 of 81), 60.0% (24 of 40), 66.7% (8 of 12), and 69.6% (16 of 23) (Fig. 2A). Thus, the higher the proportion of patients with HCV mutant-70, the higher the AFP level, and significantly lower proportions of patients with HCV mutant-70 were noted among those

with normal AFP levels (33.4%) than those with AFP levels from 1 to 2 times (53.1%) ($P = 0.001$) and above twice ULN (64.0%) ($P < 0.001$).

The proportions of patients with HCV mutant-91 among those with AFP levels below 1, from 1 to 2, from 2 to 4, from 4 to 8, and above 8 times ULN were 37.3% (154 of 413 patients), 40.7% (33 of 81), 67.5% (27 of 40), 25.0% (3 of 12), and 47.8% (11 of 23) (Fig. 2B). Thus, a higher frequency of HCV mutant-91 did not correlate with high AFP levels. In particular, significantly higher proportion of patients with HCV mutant-91 were noted among those with AFP levels from 2 to 4 times ULN (67.5%) than in those with AFP levels below 2 times (37.9%, $P < 0.001$) and above 4 times (40.0%, $P = 0.021$).

Normalization Rates of AFP Levels Based on Eradication of HCV-RNA With PEG-IFN Plus RBV Combination Therapy

Finally, the proportion of patients who showed normalization of AFP after commencement of PEG-IFN α -2b plus RBV combination therapy was determined in those at high risk for hepatocarcinogenesis, who had abnormal AFP levels (> 10 IU/L) and HCV mutant-70 at baseline. Of the 340 patients, 49 had both abnormal AFP level and HCV mutant-70 at baseline. Of these, 14.3% (7 of 49 patients) could achieve sustained virological response, 28.6% (14 of 49) showed transient virological response, and 57.1% (28 of 49) had non-virological response. Table III summarizes the characteristics of

TABLE IIB. Factors Associated with Elevated Serum AFP Above Twice the Upper Limit of Normal (≥ 21 $\mu\text{g/L}$) in Patients Infected with HCV Genotype 1b, Identified by Multivariate Analysis

Factor	Category	Odds ratio (95% CI)	P
Fibrosis stage	1: F1,2	1	
	2: F3,4	6.875 (3.485–13.56)	<0.001
Aspartate aminotransferase (IU/L)	1: <76	1	
	2: ≥ 76	6.144 (3.088–12.23)	<0.001
Substitution of aa 91	1: wild type	1	
	2: mutant type	2.101 (1.077–4.099)	0.029
Substitution of aa 70	1: wild type	1	
	2: mutant type	1.914 (0.984–3.722)	0.056

*The presence of arginine at aa 70 was evaluated as wild type, and other patterns (glutamine/histidine) as mutant type. The presence of leucine at aa 91 was evaluated as wild type, and other pattern (methionine) as mutant type. Normal reference ranges: ≤ 10 $\mu\text{g/L}$ for alpha-fetoprotein.




Fig. 2. **A:** Frequency of mutation in aa at position 70 of the HCV-1b core region according to serum AFP levels. Higher frequencies of the mutation correlated with higher serum AFP levels. Significantly lower frequencies of the mutant type were noted in patients with normal AFP levels ($\leq 10 \mu\text{g/L}$) than in those with levels from 1 to 2 times ($11\text{--}20 \mu\text{g/L}$, $P = 0.001$) and above twice the upper limit of normal ($\geq 21 \mu\text{g/L}$, $P < 0.001$), respectively. **B:** Frequency of mutation in aa at position 91 of the HCV-1b core region according to serum AFP levels. Higher frequencies of the mutation did not correlate with higher AFP levels. Significantly higher frequencies of the mutant type were noted in patients with AFP levels from 2 to 4 times the upper limit of normal ($21\text{--}40 \mu\text{g/L}$) than in those with levels below 2 times ($\leq 20 \mu\text{g/L}$, $P < 0.001$) and above 4 times ($\geq 41 \mu\text{g/L}$, $P = 0.021$).

these 49 patients at the commencement of combination therapy, according to treatment efficacy. The duration of treatment of non-virological responders was significantly shorter than that of sustained- ($P < 0.001$; Bonferroni test) and transient-virological responders ($P = 0.011$; Bonferroni test). Furthermore, AST levels of non-virological responders were significantly lower than those of sustained virological responders ($P = 0.049$; Bonferroni test). However, there were no significant differences in other patient characteristics at the commencement of treatment among the three groups.

The proportions of patients who showed normalization of AFP at the completion of treatment were 71.4% (5 of 7), 71.4% (10 of 14), and 53.6% (15 of 28) for the sustained-, transient-, and non-virological responders, respectively. There were no significant differences in the normalization rates at the completion of treatment among the three groups (Bonferroni test). However, the proportions of patients who showed

normalization of AFP at 24 weeks after completion of treatment were 100% (7 of 7), 71.4% (10 of 14), and 28.6% (8 of 28) in the sustained-, transient-, and non-virological responders, respectively. The normalization rate in non-virological responders was significantly lower than in sustained- ($P = 0.001$; Bonferroni test) and transient virological responders ($P = 0.012$; Bonferroni test) (Fig. 3).

DISCUSSION

Elevated AFP in HCV-infected patients without HCC might be useful early predictor of hepatocarcinogenesis, but there is little evidence that mild elevation of AFP in such patients is associated with eventual development of HCC. Ikeda et al. [2006] reported that AFP level above twice ULN was an independent and significant determinant of hepatocarcinogenesis in patients with HCV-related cirrhosis. The present study of HCV-infected patients treated with IFN and followed for up to 15 years also showed that the rate of hepatocarcinogenesis was significantly higher in patients with abnormal AFP levels than in those with normal levels. In particular, the rate of hepatocarcinogenesis in patients with normal AFP levels was significantly lower than in those with levels above twice the ULN, and tended to be lower than in those with levels from 1 to 2 times ULN (i.e., mild elevation of AFP). To our knowledge, the present study is the first to report the hepatocarcinogenesis rates according to AFP levels in HCV-infected patients followed over a 15-year period, including mild elevation of AFP in patients without HCC.

Despite numerous epidemiologic studies linking HCV infection and the development of HCC, it remains controversial whether HCV itself plays direct or indirect role in the pathogenesis of HCC [Koike, 2005]. Studies using transgenic mice concluded that the HCV core region can potentially cause HCC [Moriya et al., 1998], but the clinical impact of HCV core region on hepatocarcinogenesis is still not clear. Previous studies identified substitutions in aa 70 and/or 91 in the HCV-1b core region and elevated AFP levels as predictors of poor virological response to PEG-IFN plus RBV [Akuta et al., 2005, 2006, 2007a,b,c; Donlin et al., 2007], and also as risk factors for hepatocarcinogenesis [Ikeda et al., 2006; Akuta et al., 2007d]. It is speculated that cases resistant to treatment might ultimately develop HCC. The present study indicated that mutation in aa 70 in the core region predicted elevation of AFP in HCV-infected non-HCC patients. These results support the oncogenic potential of the HCV core region and clinically link mutations in this region to HCC.

Previous reports identified PA28 γ -dependent pathway as a mechanism of HCV-associated hepatocarcinogenesis. Moriishi et al. demonstrated that knockout of the PA28 γ gene induced accumulation of HCV core protein in nuclei of hepatocytes of HCV core gene transgenic mice and disrupted the development of both hepatic steatosis and HCC [Moriishi et al., 2003, 2007]. Furthermore, HCV core protein also enhanced the

TABLE III. Patient Characteristics at Commencement of Combination Therapy of Pegylated Interferon α -2b Plus Ribavirin, of 49 Patients with Abnormal AFP Levels and Mutant Type of aa 70

	SVR (n = 7)	TVR (n = 14)	NVR (n = 28)
Sex (male/female)	3/4	9/5	12/16
Age (years)*	58 (43–64)	56 (34–63)	57 (43–66)
Serum aspartate aminotransferase (IU/L)*	83 (37–324) ^a	84 (34–266)	76 (28–135)
Serum alanine aminotransferase (IU/L)*	99 (41–344)	126 (42–504)	82 (37–218)
Platelet count ($\times 10^4/\mu\text{l}$)*	11.6 (8.0–19.3)	14.1 (7.5–20.6)	12.4 (6.6–27.3)
Serum alpha-fetoprotein ($\mu\text{g/L}$)*	17 (11–161)	21 (11–38)	22 (11–427)
Fibrosis stage (F1/F2/F3/F4/ND)	0/3/2/0/2	2/0/5/0/7	6/3/7/2/10
Level of viremia (high titer/low titer)**	7/0	14/0	27/1
Amino acid substitutions in core region***			
aa 70 (wild/mutant)	0/7	0/14	0/28
aa 91 (wild/mutant)	5/2	6/8	16/12
Treatment duration (weeks)	75 (60–85) ^b	53 (46–77) ^c	47 (12–112)

Data are number of patients, except those denoted by *, which represent the median (range) values. (**) Level of viremia was evaluated as high titer (≥ 1.0 Meq/ml, or ≥ 100 KIU/ml) and low titer (< 1.0 Meq/ml, or < 100 KIU/ml). (***) The presence of arginine at aa 70 was evaluated as wild type, and other patterns (glutamine/histidine) as mutant type. The presence of leucine at aa 91 was evaluated as wild type, and other pattern (methionine) as mutant type. Normal reference ranges: 11–38 IU/L for aspartate aminotransferase; 6–50 IU/L for alanine aminotransferase (IU/L); ≤ 10 $\mu\text{g/L}$ for alpha-fetoprotein. SVR: sustained virological response; TVR: transient virological response; NVR: non-virological response; ND: not done. ^a $P = 0.049$, ^b $P < 0.001$, ^c $P = 0.011$, compared with NVR by Bonferroni test.

binding of liver X receptor α (LXR α)/retinoid X receptor α (RXR α) to the LXR-response element in the presence of PA28 γ [Moriishi et al., 2007]. Thus, PA28 γ could play a crucial role in the development of HCV-associated steatogenesis and hepatocarcinogenesis. Further studies are necessary to link the results of animal studies and the clinical impact of aa substitutions in HCV core region on hepatocarcinogenesis.

Chu et al. [2001] indicated that elevation of AFP in the absence of HCC might be associated with HCV-1b infection, and that such rise could correlate with more severe hepatic necroinflammation and fibrosis/cirrhosis and higher viremia levels. The results of the present study indicated that patients infected with HCV mutation-70 had elevated serum AFP levels, although the relation between HCV mutation-91 and AFP was not

very clear. On the one hand, multivariate analysis identified HCV mutation-91 as an independent and significant determinant of elevated AFP levels above twice the ULN. On the other; however, a significantly higher proportion of patients infected with HCV mutant-91 had AFP levels from 2 to 4 times ULN compared to those with levels below 2 times and levels above 4 times, i.e., there was no relation between the frequency of HCV mutant-91 and serum AFP levels. Further large-scale studies should be performed to investigate the relationship between HCV mutant-91 and elevated AFP.

Previous studies reported that IFN monotherapy [Arase et al., 2007] and IFN plus RBV combination therapy [Yu et al., 2006; Chen et al., 2007] results in reduction of AFP levels and the likelihood of hepatocarcinogenesis. In the present study, viral eradication (sustained virological response) in patients who received PEG-IFN plus RBV combination therapy was associated with normalization of AFP in patients at high risk for hepatocarcinogenesis (i.e., those with abnormal AFP levels and HCV mutant-70). These results emphasize that the risk of hepatocarcinogenesis could be reduced by eradication of HCV mutant-70. The results also showed that the proportion of patients with normalization of AFP levels was significantly higher in transient virological responders than in non-virological responders, suggesting that transient virological response could also result in the suppression of hepatocarcinogenesis, even when a sustained virological response is not achieved. In Japan, only 3 years had elapsed since the introduction of PEG-IFN α -2b plus RBV combination therapy into the Japanese Government Health Insurance system, and accordingly, the long-term effects of this combination therapy on hepatocarcinogenesis could not be evaluated in the present study. Further studies




Fig. 3. Normalization rates of AFP levels at and 24 weeks after completion of treatment in sustained virological responders (SVR), transient virological responders (TVR), and non-virological responders (NVR).

that include patients treated with not only IFN but also PEG-IFN plus RBV, should be performed in the future.

In conclusion, the results of the present study indicated that substitution of aa at position 70 of the HCV-1b core region can predict elevation of serum AFP levels in non-HCC patients, and that eradication of the mutant virus seems to induce normalization of AFP. This finding highlights the importance of eradication of this mutant virus in reducing the risk of hepatocarcinogenesis. The limitations of the present study were that it did not investigate other genotypes apart from HCV-1b, the geographic diversities of HCV-1b core region (distribution of wild or mutant type), and the study of other races apart from Asians in Japan. Further prospective studies, matched for HCV genotype, aa substitutions of the core region, and race, of a large group of patients are required to determine the meaning of elevated AFP in non-HCC patients.

ACKNOWLEDGMENTS

This study was supported in part by a Grant-in-Aid from the Ministry of Health, Labor, and Welfare, Japan.

REFERENCES

- Akuta N, Chayama K, Suzuki F, Someya T, Kobayashi M, Tsubota A, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H. 2001. Risk factors of hepatitis C virus-related liver cirrhosis in young adults: Positive family history of liver disease and transporter associated with antigen processing 2 (TAP2) *0201 allele. *J Med Virol* 64:109–116.
- Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2005. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology* 48:372–380.
- Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2005. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. *J Med Virol* 78:83–90.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007a. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. *J Hepatol* 46:403–410.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007b. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. *J Med Virol* 79:1686–1695.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Miyakawa Y, Kumada H. 2007c. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. *Intervirology* 50:361–368.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007d. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. *Hepatology* 46:1357–1364.
- Alpert E, Feller ER. 1978. α -Fetoprotein (AF) in benign liver disease. *Gastroenterology* 74:856–858.
- Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H. 2007. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. *J Med Virol* 79:1095–1102.
- Bayati N, Silverman AI, Gordon SC. 1998. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. *Am J Gastroenterol* 93:2452–2456.
- Bergstrand CG, Czar B. 1956. Demonstration of a new protein fraction in serum from the human fetus. *Scand J Clin Lab Invest* 8:174.
- Chayama K, Tsubota A, Arase Y, Saitoh S, Koida I, Ikeda K, Matsumoto T, Kobayashi M, Iwasaki S, Koyama S, Morinaga T, Kumada H. 1993. Genotypic subtyping of hepatitis C virus. *J Gastroenterol Hepatol* 8:150–156.
- Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN. 2007. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. *J Gastroenterol Hepatol* 22:669–675.
- Chu CW, Hwang SJ, Luo JC, Lai CR, Tsay SH, Li CP, Wu JC, Chang FY, Lee SD. 2001. Clinical, virological, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. *J Clin Gastroenterol* 32:240–244.
- Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, et al. 1989. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. *Hepatitis International Group. N Engl J Med* 321:1501–1506.
- Desmet VJ, Gerber M, Hoofnagle JH, Manna M, Scheuer PJ. 1994. Classification of chronic hepatitis: Diagnosis, grading and staging. *Hepatology* 19:1513–1520.
- Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. 1989. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. *N Engl J Med* 321:1506–1510.
- Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE. 2007. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. *J Virol* 81:8211–8224.
- Dusheiko GM. 1998. The natural course of chronic hepatitis C: Implications for clinical practice. *J Viral Hepatol* 9–12.
- Elftferious N, Heathcote J, Thomas HC, Sherlock S. 1977. Serum alpha-fetoprotein levels in patients with acute and chronic liver disease. *J Clin Pathol* 30:704–708.
- Hu KQ, Esraïlian E, Thompson K, Chase R, Kyulo N, Hassen M, Abdelhalim F, Hillebrand DJ, Runyon BA. 2002. Hepatic steatosis is associated with disease progression of chronic hepatitis C: A large cohort study in the United States. *Hepatology* 36:349A.
- Hu KQ, Kyulo N, Lim N, Elhazim B, Hillebrand DJ, Bock T. 2004. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. *Am J Gastroenterol* 99:860–865.
- Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H. 1998. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2215 patients. *J Hepatol* 28:930–938.
- Ikeda K, Arase Y, Saitoh S, Kobayashi M, Someya T, Hosaka T, Akuta N, Suzuki Y, Suzuki F, Sezaki H, Kumada H, Tanaka A, Harada H. 2006. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. *J Hepatol* 44:1089–1097.
- Johnson PJ. 2001. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. *Clin Liv Dis* 5:145–159.
- Kato N, Hijikata M, Otsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimoto K. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. *Proc Natl Acad Sci USA* 87:9524–9528.
- Kenny-Walsh E. 1999. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. *Irish Hepatology Research Group. N Engl J Med* 340:1228–1233.
- Kew MC, Purves LR, Bersohn I. 1973. Serum alpha-fetoprotein levels in acute viral hepatitis. *Gut* 14:939–942.
- Koike K. 2005. Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: Lessons from animal model studies. *Clin Gastroenterol Hepatol* 3:S132–S135.

- Moriishi K, Okabayashi T, Nakai K, Moriya K, Koike K, Murata S, Chiba S, Tanaka K, Suzuki R, Suzuki T, Miyamura T, Matsuura Y. 2003. Proteasome activator PA28 γ -dependent nuclear retention and degradation of hepatitis C virus core protein. *J Virol* 77:10237–10249.
- Moriishi K, Mochizuki R, Moriya K, Miyamoto H, Mori Y, Abe T, Murata S, Tanaka K, Miyamura T, Suzuki T, Koike K, Matsuura Y. 2007. Critical role of PA28 γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. *Proc Natl Acad Sci USA* 104:1661–1666.
- Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K. 1998. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. *Nat Med* 4:1065–1067.
- Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D, Nawrocki M, Kruska L, Hensel F, Petry W, Häussinger D. 1998. Progress of chronic hepatitis C: Results of a large, prospective cohort study. *Hepatology* 28:1687–1695.
- Okamoto K, Akuta N, Kumada H, Kobayashi M, Matsuo Y, Tazawa H. 2007. A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b. *J Virol Methods* 141:1–6.
- Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, Taketa K, Endo Y, Nagataki S. 1993. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. *N Engl J Med* 328:1802–1806.
- Silver HK, Gold P, Shuster J, Javitt NB, Freedman SO, Finlayson ND. 1974. Alpha 1-fetoprotein in chronic liver disease. *N Engl J Med* 291:506–508.
- Stein DF, Myaing M. 2002. Normalization of markedly elevated α -fetoprotein in a virologic nonresponder with HCV-related cirrhosis. *Dig Dis Sci* 47:1686–2690.
- Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF. 2006. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: A nationwide, multi-centre study in Taiwan. *Antivir Ther* 11:985–994.

Efficacy of Low-Dose Intermittent Interferon-Alpha Monotherapy in Patients Infected With Hepatitis C Virus Genotype 1b Who Were Predicted or Failed to Respond to Pegylated Interferon Plus Ribavirin Combination Therapy

Norio Akuta,^{1*} Fumitaka Suzuki,¹ Yusuke Kawamura,¹ Hiromi Yatsuji,¹ Hitomi Sezaki,¹ Yoshiyuki Suzuki,¹ Tetsuya Hosaka,¹ Masahiro Kobayashi,¹ Mariko Kobayashi,² Yasuji Arase,¹ Kenji Ikeda,¹ and Hiromitsu Kumada¹

¹Department of Hepatology, Toranomon Hospital, Tokyo, Japan

²Liver Research Laboratory, Toranomon Hospital, Tokyo, Japan

The efficacy of interferon (IFN) monotherapy for non-responders to pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy is still unclear. To evaluate the impact of IFN monotherapy on biochemical response, 200 consecutive patients infected with HCV genotype 1b, who received low-dose intermittent IFN-alpha monotherapy, were investigated. A median IFN dose per day of 3 million units was administered during a median period of 74 weeks. As a whole, the ALT normalization rates were 50.5, 65.9, 58.4, and 61.7% at 4, 12, 24, and 48 weeks, respectively. In 40 patients, who had abnormal AFP levels at the start of treatment, 52.5% achieved normalization of AFP within 48 weeks. Multivariate analysis identified indocyanine green retention rate at 15 min as the parameter that influenced significantly and independently ALT normalization. ALT normalization rates of patients who were predicted to be poor responders to PEG-IFN plus RBV combination therapy (but not substitutions of amino acid 70 and/or 91 in the HCV core region, female sex, and lower levels of low-density lipoprotein cholesterol) were similar to others. Furthermore, the ALT normalization rates in non-responders to combination therapy were 29.2, 60.9, 60.0, and 40.0% at 4, 12, 24, and 48 weeks, respectively. The results suggest that low-dose intermittent IFN monotherapy is an efficacious therapeutic regimen for patients unsuitable for PEG-IFN plus RBV, including non-responders, because it can lead to ALT normalization and thus a reduced risk of hepatocarcinogenesis. *J. Med. Virol.* 80:1363–1369, 2008. © 2008 Wiley-Liss, Inc.

KEY WORDS: HCV; interferon; ribavirin; ALT; hepatocellular carcinoma; core

region; AFP; low-density lipoprotein cholesterol

INTRODUCTION

Hepatitis C virus (HCV) usually causes chronic infection, which can result in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) [Dush-eiko, 1998; Ikeda et al., 1998; Niederau et al., 1998; Kenny-Walsh, 1999; Akuta et al., 2001]. Treatment of HCV-chronic hepatitis with interferon (IFN) can induce viral clearance and marked biochemical and histological improvement [Davis et al., 1989; Di Bisceglie et al., 1989].

Pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy for chronic HCV infection is expensive and associated with severe side effects but treated patients show a high-sustained virological response. Patients who do not achieve sustained virological response need to be identified before the start of combination therapy, in order to avoid unnecessary side effects and high costs. Thus, the safer IFN monotherapy should be selected as the therapeutic regimen for patients unsuitable for PEG-IFN plus RBV therapy. In a series of papers, Akuta et al. [2005a, 2006, 2007a,b,c] studied determinants of the response to PEG-IFN plus RBV in patients with high titers of genotype 1b (≥ 100 kiloIU [KIU]/ml), which is

Grant sponsor: Ministry of Health, Labor and Welfare, Japan (partial support).

*Correspondence to: Norio Akuta, MD, Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-0001, Japan. E-mail: akuta-gi@umin.ac.jp

Accepted 9 April 2008

DOI 10.1002/jmv.21224

Published online in Wiley InterScience
(www.interscience.wiley.com)

dominant in Japan. They identified substitutions of amino acid (aa) 70 and/or 91 in the HCV core region, female sex, and low levels of low-density lipoprotein cholesterol as independent and significant pretreatment negative predictors associated with virological response. Furthermore, previous studies reported that low-dose intermittent IFN monotherapy, as a treatment strategy, induces biochemical response [i.e., normalization of alanine aminotransferase (ALT) and alpha-fetoprotein (AFP) levels] and reduces the risk of hepatocarcinogenesis, even if patients failed to achieve sustained virological response [Arase et al., 2001, 2007; Nomura et al., 2007; McHutchison et al., 2008]. Hence, low-dose intermittent IFN monotherapy might be beneficial therapeutically in reducing the risk of hepatocarcinogenesis in patients who are predicted to be non-responsive to PEG-IFN plus RBV.

The present study included 200 consecutive patients infected with HCV genotype 1b, who were treated by self-injection of low-dose intermittent natural IFN-alpha. The aims of the study were the following. (1) To investigate the normalization rates of alanine aminotransferase (ALT) and α -fetoprotein (AFP) levels within 48 weeks after the commencement of treatment. (2) To examine the predictive factors associated with ALT normalization. (3) To evaluate the efficacy of IFN monotherapy in patients with predictors of poor response to IFN plus RBV combination therapy. (4) To evaluate the efficacy of IFN monotherapy for non-responders to IFN plus RBV combination therapy.

PATIENTS AND METHODS

Patients

Among 252 consecutive HCV-infected patients who started IFN monotherapy between April 2005 and July 2007 at Toranomon Hospital, 200 were selected in the present study based on the following criteria. (1) Patients treated by self-injection of natural IFN-alpha (Sumiferon[®]; Sumitomo Pharmaceutical Co., Osaka, Japan). (2) Patients infected with HCV genotype 1b alone. (3) Patients negative for hepatitis B surface antigen (radioimmunoassay, Dainabot, Tokyo, Japan), positive for anti-HCV (third-generation enzyme immunoassay, Chiron Corp, Emerville, CA), and positive for HCV RNA qualitative analysis with PCR (Amplicor, Roche Diagnostic Systems, Pleasanton, CA). (4) Patients who have not been treated with antiviral or immunosuppressive agents, except for IFN plus RBV combination therapy, within 6 months of enrolment. (5) Patients free of HCC. (6) Patients free of coinfection with human immunodeficiency virus. (7) Lifetime cumulative alcohol intake <500 kg (mild to moderate alcohol intake). (8) Patients free of other types of hepatitis, including hemochromatosis, Wilson disease, primary biliary cirrhosis, alcoholic liver disease, and autoimmune liver disease, and (9) patients who consented to the study.

With regard to the clinical features of 200 patients at the start of IFN monotherapy, there were 103 men and

97 women, aged 27–77 with a median age of 62 years. The median ALT level was 80 IU/L (range, 6–487 IU/L), and the median platelet count was $13.0 \times 10^4/\text{mm}^3$ (range, 3.8×10^4 – $28.0 \times 10^4/\text{mm}^3$). The median viremia level was 1,200 KIU/ml (range, 5–>5,000 KIU/ml) (Table I). Furthermore, 162 of the 200 patients (81%) received IFN-alpha monotherapy by three times per week; the remaining 38 patients (19%) received IFN-alpha monotherapy that included an initial daily administration in the first 8 weeks, followed by three times per week. A median IFN dose per day of 3 million units (MU, range; 3–6 MU) was administered during a median period of 74 weeks (range; 2–118 weeks). Of the 200 patients, 40 had not achieved sustained virological response with prior therapy of IFN plus RBV, and especially 27 patients of them had been treated with adequate combination therapy for at least 24 weeks (median, 43 weeks; range, 24–73 weeks).

Efficient treatment represented normalization of ALT levels (normal reference ranges: 6–50 IU/L) and AFP levels (normal reference ranges: $\leq 20 \mu\text{g/L}$) during and at the end of 48-week treatment protocol.

The study protocol was approved by the Human Ethics Review Committee of Toranomon Hospital.

Laboratory Investigations

Blood samples were obtained at least once every month from the commencement of treatment, and were tested for ALT and AFP levels. The serum samples were frozen at -80°C within 4 hr of collection and then thawed at the time of measurement. HCV genotype was determined by PCR using a mixed primer set derived from the nucleotide sequences of NS5 region [Chayama et al., 1993]. HCV-RNA level was measured quantitatively by PCR (Cobas Amplicor HCV monitor v 2.0 using the 10-fold dilution method, Roche Diagnostics, Indianapolis, IN) at the commencement of treatment. The lower detection limit of the assay was 5 KIU/ml.

Detection of Amino Acid Substitutions in Core Region

With use of HCV-J (accession no. D90208) as a reference [Kato et al., 1990], the sequence of 1–191 aa in the core protein of genotype 1b was determined, and it was compared with the consensus sequence constructed on 50 clinical samples [Akuta et al., 2005a] for detecting substitutions at aa 70 of arginine (wild) or glutamine/histidine (mutant) and aa 91 of leucine (wild) or methionine (mutant). In the present study, aa substitutions of the core region were analyzed by direct sequencing [Akuta et al., 2005a, 2006]. The PCR genotyping could be performed in 193 patients; the remaining seven patients could not be analyzed due to the lack of adequate serum samples obtained before treatment.

Histopathological Examination of the Liver

Liver biopsy specimens were obtained percutaneously or at peritoneoscopy using a modified Vim Silverman

TABLE I. Patient Profile and Laboratory Data at Commencement of Interferon Monotherapy in 200 Patients Infected With HCV Genotype 1b

Demographic data	
Number of patients	200
Sex (M/F)	103/97
Age (years)*	62 (27–77)
History of blood transfusion	81 (40.5%)
Family history of liver disease	58 (29.0%)
Body mass index (kg/m ²)*	22.8 (15.6–32.9)
Laboratory data*	
Serum aspartate aminotransferase (IU/L)	69 (18–756)
Serum alanine aminotransferase (IU/L)	80 (6–487)
Serum albumin (g/dl)	3.7 (2.6–4.4)
Gamma-glutamyl transpeptidase (IU/L)	49 (11–368)
Leukocyte count (/mm ³)	4,000 (1,700–8,100)
Hemoglobin (g/dl)	13.9 (8.9–17.3)
Platelet count (×10 ⁴ /mm ³)	13.0 (3.8–28.0)
Indocyanine green retention rate at 15 min (%)	20 (4–62)
Serum iron (μg/dl)	146 (37–322)
Serum ferritin (μg/L)	136 (<10–1,308)
Creatinine clearance (ml/min)	99 (13–167)
Level of viremia (KIU/ml)	1,200 (5–>5,000)
Alpha-fetoprotein (μg/L)	9 (2–398)
Total cholesterol (mg/dl)	165 (15–296)
High-density lipoprotein cholesterol (mg/dl)	45 (21–80)
Low-density lipoprotein cholesterol (mg/dl)	96 (43–237)
Triglycerides (mg/dl)	93 (46–228)
Uric acid (mg/dl)	5.4 (2.8–9.4)
Fasting blood sugar (mg/dl)	97 (67–228)
Histological findings	
Stage of fibrosis (F1/F2/F3/F4/ND)	45/42/35/19/59
Hepatocyte steatosis (none to mild/moderate to severe/ND)	90/24/86
Treatment	
Interferon dose (million units/day)	3 (3–6)
Presence of initial daily interferon administration	38 (19.0%)
Amino acid substitutions in the core region ^a	
aa 70 (wild/non-wild/ND)	118/72/3
aa 91 (wild/non-wild/ND)	124/69/0
aa 70 and aa 91 (double wild/non-double wild/ND)	76/115/2

Data are number and percentage of patients, except those denoted by *, which represent the median (range) values.

Two patterns of mutant and competitive are indicated as non-wild. The pattern of wild at aa 70 and wild at aa 91 was evaluated as double wild-type, and the other patterns were non-double wild-type. ND, not determined.

^aAmino acid substitutions were evaluated in 193 patient using pretreatment sera by direct sequencing.

needle with an internal diameter of 2 mm (Tohoku University style, Kakinuma Factory, Tokyo, Japan), fixed in 10% formalin, and stained with hematoxylin and eosin, Masson's trichrome, silver impregnation, and periodic acid-Schiff after diastase digestion. All specimens for examination contained six or more portal areas. Histopathological diagnosis was made by an experienced liver pathologist (HK) who was blinded to the clinical data. Chronic hepatitis was diagnosed based on histopathological assessment according to the scoring system of Desmet et al. [1994].

Follow-Up

Clinical and laboratory assessments were performed at least once every month from the commencement of treatment. Adverse effects were monitored clinically by careful interviews and medical examination at least once every month. Patient compliance with treatment was evaluated with a questionnaire. Blood samples were also obtained at least once every month from the commencement of treatment, and were also analyzed

for levels of ALT and AFP at various time points. Follow-up time represented the time from the start of treatment until the stop of treatment, or until the last visit.

Statistical Analysis

Analysis of efficacy of treatment was performed on an intention to treat basis. The χ^2 test, Fisher's exact probability test, and Mann-Whitney's *U*-test were used to compare the background characteristics between groups. The cumulative ALT normalization rates were calculated using the Kaplan-Meier technique; differences between the curves were tested using the log-rank test. Statistical analyses of ALT normalization according to groups were calculated using the period from the commencement of IFN monotherapy. Stepwise Cox regression analysis was used to determine independent predictive factors that were associated with ALT normalization within 48 weeks after the commencement of treatment. The odds ratios and 95% confidence intervals (95%CI) were also calculated. Potential predictive factors associated with ALT normalization

included the following 29 variables: sex, age, history of blood transfusion, family history of liver disease, body mass index, AST, ALT, albumin, γ GTP, leukocyte count, hemoglobin, platelet count, indocyanine green retention rate at 15 min, serum iron, serum ferritin, creatinine clearance, level of viremia, AFP, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, uric acid, fasting blood sugar, fibrosis stage, hepatocyte steatosis, IFN dose per day, and presence of initial daily IFN administration. Each variable was transformed into categorical data consisting of two simple ordinal numbers for univariate and multivariate analyses. Variables that achieved statistical significance ($P < 0.05$) or marginal significance ($P < 0.10$) on univariate analysis were entered into a multivariate Cox proportional hazard model to identify significant independent factors. Statistical comparisons were performed using the SPSS software (SPSS, Inc., Chicago, IL). All P values of less than 0.05 by the two-tailed test were considered significant.

RESULTS

Efficacy of IFN Monotherapy

The rates of ALT normalization in the intention to treat population analysis were evaluated at 0, 4, 12, 24, and 48 weeks after commencement of treatment. As a whole, the rates were 18.0% (36/200), 50.5% (94/186), 65.9% (116/176), 58.4% (90/154), and 61.7% (71/115), respectively. Thus, ALT normalization rates favorably exceeded 50% at 4 weeks. Furthermore, in 40 patients with abnormal AFP levels (≥ 21 $\mu\text{g/L}$) at the commencement of treatment, AFP levels of 92.5% (37/40)

decreased and those of 7.5% (3/40) increased within 48 weeks. Especially, 52.5% (21/40) achieved normalization of AFP within 48 weeks. These results indicate that low-dose intermittent IFN monotherapy achieved favorable biochemical response.

Predictive Factors Associated With ALT Normalization by Univariate and Multivariate Analysis

The data for the whole population sample were analyzed to determine those factors that could predict ALT normalization within 48 weeks after the commencement of treatment. Univariate analysis identified nine parameters that tended to or significantly correlated with ALT normalization. These included AST ($P = 0.007$), ALT ($P = 0.009$), γ GTP ($P = 0.075$), platelets ($P = 0.093$), fibrosis stage ($P = 0.066$), indocyanine green retention rate at 15 min ($P = 0.026$), serum iron ($P = 0.003$), high-density lipoprotein cholesterol ($P = 0.067$), and AFP ($P = 0.046$). These factors were entered into multivariate analysis, which then identified indocyanine green retention rate at 15 min ($P = 0.027$) as the parameter that influenced significantly and independently ALT normalization (Table II).

Efficacy of IFN Monotherapy in Patients With Predictors of Poor Response to PEG-IFN Plus RBV Combination Therapy

Figure 1 shows the prevalence with respect to ALT normalization rates in patients with predictors of poor response to PEG-IFN plus RBV combination therapy.

TABLE II. Factors Associated With ALT Normalization During Interferon Monotherapy, Identified by Univariate and Multivariate Analysis

Factor	Category	Univariate Cox proportional hazard model		Multivariate Cox proportional hazard model	
		Odds ratio (95% CI)	P	Odds ratio (95% CI)	P
Aspartate aminotransferase (IU/L)	1: <70	1		—	—
	2: ≥ 70	0.589 (0.400–0.867)	0.007	—	—
Alanine aminotransferase (IU/L)	1: <75	1		—	—
	2: ≥ 75	0.588 (0.395–0.875)	0.009	—	—
γ -Glutamyl transpeptidase (IU/L)	1: <50	1		—	—
	2: ≥ 50	0.636 (0.386–1.047)	0.075	—	—
Platelets ($\times 10^4/\text{mm}^3$)	1: <15.0	1		—	—
	2: ≥ 15.0	1.397 (0.946–2.064)	0.093	—	—
Fibrosis stage	1: 1,2	1		—	—
	2: 3,4	0.627 (0.381–1.031)	0.066	—	—
Indocyanine green retention rate at 15 min (%)	1: <20	1		1	—
	2: ≥ 20	0.557 (0.333–0.932)	0.026	0.503 (0.274–0.925)	0.027
Serum iron ($\mu\text{g/dl}$)	1: <150	1		—	—
	2: ≥ 150	0.522 (0.342–0.797)	0.003	—	—
High-density lipoprotein cholesterol (mg/dl)	1: <45	1		—	—
	2: ≥ 45	1.468 (0.973–2.215)	0.067	—	—
Alpha-fetoprotein ($\mu\text{g/L}$)	1: <10	1		—	—
	2: ≥ 10	0.662 (0.441–0.992)	0.046	—	—

Only variables that achieved statistical significance ($P < 0.05$) or marginal significance ($P < 0.10$) on univariate and multivariate Cox proportional hazard model are shown.

95% CI, 95% confidence interval.

J. Med. Virol. DOI 10.1002/jmv

According to the substitutions of core aa 70 and aa 91, the ALT normalization rates were 15.7% (18/115) versus 22.4% (17/76) at 0 week, 42.6% (46/108) versus 61.4% (43/70) at 4 weeks, 62.1% (64/103) versus 69.7% (46/66) at 12 weeks, 59.3% (54/91) versus 56.1% (32/57) at 24 weeks, and 58.5% (38/65) versus 63% (29/46) at 48 weeks for non-double wild-type and double wild-type, respectively [not significantly different, except for 4 weeks ($P = 0.021$), Fig. 1A].

According to sex, the ALT normalization rates were 22.7% (22/97) versus 13.6% (14/103) at 0 week, 50.6% (44/87) versus 50.5% (50/99) at 4 weeks, 66.3% (53/80) versus 65.6% (63/96) at 12 weeks, 62.7% (42/67) versus 55.2% (48/87) at 24 weeks, and 67.3% (33/49) versus 57.6% (38/66) at 48 weeks for female and male, respectively (not significant, Fig. 1B).

According to the levels of low-density lipoprotein cholesterol, the ALT normalization rates were 15.5% (9/58) versus 20.0% (23/115) at 0 week, 37.0% (20/54) versus 54.1% (59/109) at 4 weeks, 58.8% (30/51) versus 66% (68/103) at 12 weeks, 58.5% (24/41) versus 53.8% (49/91) at 24 weeks, and 66.7% (22/33) versus 57.4% (39/68) at 48 weeks for low levels (<86 mg/dl) and high levels (≥ 86 mg/dl), respectively [not significant, except for 4 weeks ($P = 0.047$), Fig. 1C].

The above results indicate that in low-dose intermittent IFN monotherapy, ALT normalization rates of

patients with predictors of poor response were not different from those without such predictors.

Efficacy of IFN Monotherapy in Non-Responders to IFN Plus RBV Combination Therapy

The rates of ALT normalization were evaluated in 27 patients who had received prior therapy with adequate IFN plus RBV for at least 24 weeks but showed no sustained virological response. The rates were 14.8% (4/27), 29.2% (7/24), 60.9% (14/23), 60% (12/20), and 40.0% (4/10) at 0, 4, 12, 24, and 48 weeks, respectively. Thus, ALT normalization rates favorably exceeded 60% at 12 weeks. These results indicate that non-responders to IFN plus RBV treated again with low-dose intermittent IFN monotherapy can achieve a favorable biochemical response.

DISCUSSION

For chronic HCV infection, PEG-IFN plus RBV combination therapy is expensive, associated with severe side effects but results in a high-sustained virological response. However, it is desirable to identify those patients who do not achieve sustained virological response before the start of the combination therapy in order to free them of unnecessary side effects and high costs. One alternative option for such patients is IFN




Fig. 1. The ALT normalization rates at 0, 4, 12, 24, and 48 weeks after commencement of IFN monotherapy, according to (A) substitutions of core aa 70 and aa 91, (B) sex, and (C) the levels of low-density lipoprotein cholesterol.

monotherapy, which could reduce the risk of hepatocarcinogenesis [Arase et al., 2001, 2007; Akuta et al., 2005a,b; Donlin et al., 2007; Nomura et al., 2007; McHutchison et al., 2008].

The efficacy of IFN monotherapy in patients who are predicted to respond poorly to IFN plus RBV combination therapy is still unknown. Previous results identified substitutions of aa 70 and/or 91 in the core region, female sex, and lower levels of low-density lipoprotein cholesterol as independent and significant pretreatment negative predictors associated with virological response [Akuta et al., 2005a, 2006, 2007a,b,c]. These studies also showed that substitutions of aa 70 and/or 91 are risk factors for hepatocarcinogenesis in the same patients [Akuta et al., 2007d]. The present study of low-dose intermittent IFN monotherapy showed that ALT normalization rates of patients who were predicted to have a poor response to the combination therapy were not different from others. It is important to achieve a better biochemical response regardless of core aa substitutions as risk factor of hepatocarcinogenesis. Thus, a low-dose intermittent IFN monotherapy for patients predicted to fail to respond to PEG-IFN plus RBV is an efficacious therapeutic regimen for normalization of ALT and thus reduction of risk of hepatocarcinogenesis.

The efficacy of IFN monotherapy for non-responders to IFN plus RBV combination therapy is still controversial. In the present study of low-dose intermittent IFN monotherapy, ALT normalization rates in non-responders to combination therapy favorably exceeded 60% at 12 weeks. Di Bisceglie et al. [2007] reported recently that maintenance therapy with PEG-IFN alpha-2a for non-responder to combination therapy was associated with significant decreases in ALT levels, but the rate of disease progression was similar in treated (34.1%) and untreated (33.8%) groups. The discrepancy between the present results and those of HALT-C trial may be due to one or more factors. The first reason for the difference is probably the large number of cirrhotic patients (about 40% of all) in HALT-C trial. The second reason is probably related to the difference in the efficacy measures used in HALT-C trial, which evaluated decreases in ALT levels regardless of ALT normalization or not. The third reason is probably related to the study design of HALT-C trial with PEG-IFN alpha-2a for non-responders to combination therapy [Di Bisceglie et al., 2007]. Large-scale prospective randomized controlled trials should be conducted in the future to confirm whether low-dose intermittent IFN monotherapy could reduce the risk of hepatocarcinogenesis based on ALT normalization for non-responders to PEG-IFN plus RBV combination therapy.

The present results based on multivariate analysis showed that a high level of indocyanine green retention rate at 15 min is a negative predictor of ALT normalization during the course of low-dose intermittent IFN monotherapy. Previous data indicated that absence of advanced liver fibrosis is a positive predictor of sustained virological response to IFN monotherapy and IFN plus RBV combination therapy [Jouet et al.,

1994; Poynard et al., 2000; Bruno et al., 2004]. Akuta et al. [2005a, 2007a] also showed previously that high levels of indocyanine green retention rate at 15 min or low levels of serum albumin are associated with advanced liver fibrosis, and that they are independent and significant negative predictors of the virological response to PEG-IFN plus RBV. To our knowledge, this is the first report that describes the relationship between indocyanine green retention rate at 15 min level and biochemical response during IFN monotherapy. Di Bisceglie et al. [2007] recently reported that maintenance therapy with PEG-IFN alpha-2a failed to halt liver disease progression in patients with advanced hepatic fibrosis. Further studies of large number of patients are required to investigate the relationship between severity of histopathological liver changes and biochemical response during low-dose intermittent IFN monotherapy.

One limitation of the present study was that viral factors other than the core region of HCV genome were not examined, such as the interferon sensitivity determining region (ISDR) and the interferon/ribavirin resistance determining region (IRRDR) of NS5A region [Enomoto et al., 1995, 1996; El-Shamy et al., 2007]. Biochemical response during low-dose intermittent IFN monotherapy seems to be based on a dynamic tripartite interaction of virus, host, and treatment regimen. Further understanding of the complex interaction between these factors should facilitate the development of more effective therapeutic regimens.

In conclusion, the present study showed that one therapeutic regimen that can reduce the risk of hepatocarcinogenesis based on ALT normalization is low-dose intermittent IFN monotherapy, for patients unsuitable for PEG-IFN plus RBV including non-responders. Large-scale prospective randomized controlled trials should be conducted to confirm this finding.

REFERENCES

- Akuta N, Chayama K, Suzuki F, Someya T, Kobayashi M, Tsubota A, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H. 2001. Risk factors of hepatitis C virus-related liver cirrhosis in young adults: Positive family history of liver disease and transporter associated with antigen processing 2 (TAP2) *0201 allele. *J Med Virol* 64:109–116.
- Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2005a. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology* 48:372–380.
- Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. 2005b. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: Multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. *Scand J Gastroenterol* 40:688–696.
- Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2006. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load. *J Med Virol* 78:83–90.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007a. Predictive factors of early and sustained responses to

- peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. *J Hepatol* 46:403–410.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007b. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. *J Med Virol* 79:1686–1695.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Miyakawa Y, Kumada H. 2007c. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. *Intervirology* 50:361–368.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007d. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. *Hepatology* 46:1357–1364.
- Arase Y, Chayama K, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Suzuki F, Akuta N, Someya T, Kobayashi M, Kumada H. 2001. Randomized controlled clinical trial of lymphoblastoid interferon-alpha for chronic hepatitis C. *Hepatology* 21:55–66.
- Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H. 2007. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. *J Med Virol* 79:1485–1490.
- Bruno S, Camma C, Di Marco V, Rumi M, Vinci M, Camozzi M, Rebutti C, Di Bona D, Colombo M, Craxi A, Mondelli MU, Pinzello G. 2004. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: A randomized controlled trial. *J Hepatol* 41:474–481.
- Chayama K, Tsubota A, Arase Y, Saitoh S, Koida I, Ikeda K, Matsumoto T, Kobayashi M, Iwasaki S, Koyama S, Morinaga T, Kumada H. 1993. Genotypic subtyping of hepatitis C virus. *J Gastroenterol Hepatol* 8:150–156.
- Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer Jr. HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitz J, Albrecht J, Meschivitz C, Ortego TJ, Gibas A. 1989. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. Hepatitis Interventional Group. *N Engl J Med* 321:1501–1506.
- Desmet VJ, Gerber M, Hoofnagle JH, Manna M, Scheuer PJ. 1994. Classification of chronic hepatitis: Diagnosis, grading and staging. *Hepatology* 19:1513–1520.
- Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. 1989. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized double blind, placebo controlled trial. *N Engl J Med* 321:1506–1510.
- Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky H, Morgan TR, Dienstag JL, Ghany M, Morishima C, Snow KK. 2007. Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: Results of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. *Hepatology* 46:290A.
- Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE. 2007. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. *J Virol* 81:8211–8224.
- Dusheiko GM. 1998. The natural course of chronic hepatitis C: Implications for clinical practice. *J Viral Hepatol* 5(Suppl 1):9–12.
- El-Shamy A, Sasayama M, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. 2007. Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pretreatment sera. *Microbiol Immunol* 51:471–482.
- Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. 1995. Comparison of full-length sequences of interferon sensitive and resistant hepatitis C virus 1b. *J Clin Invest* 96:224–230.
- Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 334:77–81.
- Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H. 1998. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2215 patients. *J Hepatol* 28:930–938.
- Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM. 1994. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. *Gastroenterology* 106:686–690.
- Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimoto K. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. *Proc Natl Acad Sci USA* 87:9524–9528.
- Kenny-Walsh E. 1999. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. *Irish Hepatology Research Group. N Engl J Med* 340:1228–1233.
- McHutchinson JG, Patel K, Schiff ER, Gitlin N, Mur RE, Everson GT, Carithers RL Jr, Davis GL, Marcellin P, Shiffman ML, Harver J, Albercht JK. 2008. Clinical trial: Interferon alfa-2b continuous long-term therapy versus repeated 24-week cycles for retreating chronic hepatitis C. *Aliment Pharmacol Ther* 27:422–432.
- Niederer C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D, Nawrocki M, Kruska L, Hensel F, Petry W, Häussinger D. 1998. Progress of chronic hepatitis C: Results of a large, prospective cohort study. *Hepatology* 28:1687–1695.
- Nomura H, Kashiwagi Y, Hirano R, Tanimoto H, Tsutsumi N, Higashi M, Ishibashi H. 2007. Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: A pilot study. *Hepatology* 37:490–497.
- Poynard T, McHutchinson J, Goodman Z, Ling MH, Albrecht J. 2000. Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Group. *Hepatology* 31:211–218.

Efficacy in Patients with Dose Reduction in Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C

Yasuji Arase^a Fumitaka Suzuki^a Hitomi Sezaki^a Yusuke Kawamura^a
Yoshiyuki Suzuki^a Masahiro Kobayashi^a Norio Akuta^a Tetsuya Hosaka^a
Hiromi Yatsuji^a Miharuru Hirakawa^a Mariko Kobayashi^b Kenji Ikeda^a
Hiromitsu Kumada^a

^aDepartment of Hepatology and ^bHepatic Research Unit, Toranomon Hospital, Tokyo, Japan

Key Words

Chronic hepatitis C · Peginterferon · Ribavirin · Dose reduction

Abstract

Objective: The aim of this study was to elucidate efficacy after dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C. **Methods:** Inclusion criteria were hepatitis C virus (HCV) genotype 1b, serum HCV RNA level of ≥ 100 KIU/ml, dose reduction of peginterferon and/or ribavirin between the first 4 weeks and 20 weeks after the initiation of treatment. 164 patients were enrolled in this retrospective cohort study. Predictive factors for sustained viral response (SVR) after dose reduction were examined. **Results:** Out of the 146 patients treated with dose reduction, 57 had SVR. Multivariate analysis showed that SVR occurred when serum HCV RNA at the time of dose reduction was negative ($p < 0.001$) and total ribavirin dose was $\geq 100\%$ of the anticipated total dose ($p < 0.001$). 57% (55/97) of patients with undetectable serum HCV RNA at the time of dose reduction had SVR. In contrast, only 4% (2/49) of patients with detectable serum HCV RNA at the time of dose reduction had SVR. **Conclusions:** On dose reduction of com-

bination therapy for chronic hepatitis C, undetectable serum HCV RNA at the time of dose reduction and attainment of the total ribavirin dose of $\geq 100\%$ enhance SVR.

Copyright © 2008 S. Karger AG, Basel

Introduction

Combination therapy of peginterferon and ribavirin for hepatitis C virus (HCV) induces sustained virological response (SVR) in 50–60% of cases with genotype 1 and in 80–90% of cases with genotype 2. These SVR rates in patients treated with combination of peginterferon and ribavirin were higher than those treated with interferon (IFN) alone [1–6]. Thus, combination therapy of peginterferon and ribavirin has been recommended as a first choice for chronic hepatitis C. However, combination therapy has been associated with various adverse events, such as psychological disturbances, poor appetite, skin rash, infection, anemia and leukopenia [1, 2, 5, 7]. Dose reduction or even discontinuation of treatment often becomes necessary in combination therapy for chronic hepatitis C. In several studies, the reduction rate due to severe side effects was reported to be about 25–40%.

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2008 S. Karger AG, Basel
0300–5526/08/0511–0001\$24.50/0

Accessible online at:
www.karger.com/int

Yasuji Arase, MD
Department of Hepatology, Toranomon Hospital
2-2-2 Toranomon, Minato-ku
Tokyo 105-8470 (Japan)
Tel. +81 3 3588 1111, Fax +81 3 3582 7068, E-Mail es9y-ars@asahi-net.or.jp

Some authors have reported that adherence to combination therapy enhanced sustained virological eradication in genotype 1 with chronic hepatitis C [8–12]. In the present study, we evaluated the efficacy after dose reduction of combination therapy in Japanese patients. The study design is non-randomized retrospective cohort study.

Materials and Methods

Patients

Eligibility criteria for entry into the study included the following: (1) HCV genotype 1b; (2) serum level of HCV RNA of ≥ 100 KIU/ml; (3) dose reduction of peginterferon and ribavirin between the first 4 weeks and 20 weeks after the initiation of combination therapy; (4) no corticosteroid, immunosuppressive agents, or antiviral agents used within 6 months; (5) no hepatitis B surface antigens, antinuclear antibodies, or antimitochondrial antibodies detectable in serum, determined by radioimmunoassay, and (6) leukocytes $>2,000/\text{mm}^3$, platelet count $>80,000/\text{mm}^3$, and bilirubin <2.0 mg/ml. We excluded from the study all the patients with the following: (1) a history of alcohol abuse; (2) advanced liver cirrhosis of encephalopathy, bleeding esophageal varices, or ascites. The Institutional Ethics Review Board of our hospital approved our study. The physician in charge explained the purpose and method of this clinical trial, as well as the potential adverse reactions, to each patient, who later gave his/her informed consent for participation.

Combination Therapy of Pegylated-IFN and Ribavirin

For the treatment regimen, the peginterferon (Peg-intron; Schering-Plough Pharmaceutical Co., Osaka, Japan) and ribavirin (Rebetol; Schering-Plough Pharmaceutical Co.) were given based on body weight. At the initiation of combination therapy, patients received peginterferon at a median dose of $1.5 \mu\text{g}/\text{kg}$ (range 1.2 – $1.6 \mu\text{g}/\text{kg}$) subcutaneously each week and oral ribavirin at a median dose of $11.9 \text{ mg}/\text{kg}$ (range 10.0 – $16.3 \text{ mg}/\text{kg}$) daily. The peginterferon dose was adjusted according to body weight ($60 \mu\text{g}$ for ≤ 40 kg, $80 \mu\text{g}$ for >40 and ≤ 60 kg, $100 \mu\text{g}$ for >60 and ≤ 80 kg, and $120 \mu\text{g}$ for >80 and ≤ 100 kg). The ribavirin dose was adjusted according to body weight (600 mg for ≤ 60 kg, 800 mg for >60 and ≤ 80 kg, and $1,000 \text{ mg}$ for >80 kg).

The physician in charge reduced the dose of treatment when the blood cell count decreased. Peginterferon was stepwise reduced $20 \mu\text{g}/\text{week}$ if the WBC declined to $<1,500/\text{mm}^3$, leukocyte count to $<750/\text{mm}^3$ or platelet count to $<80,000/\text{mm}^3$. Ribavirin was stepwise reduced 200 mg if the hemoglobin level declined to $\leq 10 \text{ g}/\text{dl}$. The doses of peginterferon and ribavirin could be increased back to starting doses if these adverse events resolved. The amounts of both medications taken by each patient were expressed as a percentage of the anticipated total dose in the 48-week treatment regimen based on body weight. The median duration of treatment was 48 weeks (range 8–96 weeks). A SVR to therapy was defined as clearance of HCV RNA by commercial amplicor HCV qualitative assay (Amplicor HCV, Version 2.0; Roche Diagnostic Systems, Basel, Switzerland) at 6 months after the cessation of combination therapy [13].

Blood samples were obtained just before and 6 months after combination therapy. The samples were stored at -80° until analyzed. Using these blood samples, the HCV RNA level before IFN therapy was analyzed by quantitative PCR assay (Amplicor GT-HCV Monitor Version 2.0; Roche Molecular Systems) [14]. HCV genotype was examined by polymerized chain reaction assay, using a mixture of primers for the six subtypes known to exist in Japan, as reported previously [15]. The start of the follow-up period was defined as the first day of dose reduction in combination therapy. Clinical evaluation and biochemical and hematological tests were performed at 1- to 4-weekly intervals. We evaluated the following: (1) SVR after dose reduction, and (2) predictive factors for SVR after reduction based on combination therapy-related side effects.

Liver Histology before IFN Therapy

Liver biopsy specimens were obtained percutaneously under the observation by laparoscopy using a modified Vim Silverman needle with an internal diameter of 2 mm (Tohoku University style, Kakinuma Factory, Tokyo, Japan), fixed in 10% formalin, and stained with hematoxylin and eosin, Masson's trichrome, silver impregnation, and periodic acid-Schiff after diastase digestion. The biopsy specimens were scored according to the system of Desmet et al. [16].

Statistical Analysis

A Cox proportional hazards model was used to analyze the factors contributing to the stop of treatment and dose reduction due to combination therapy: factors examined included age, sex, body mass index, histological findings, HCV load, ALT, hemoglobin, WBC, platelet count, HCV RNA at the time of dose reduction, total ribavirin dose and peginterferon dose. Significance of trends in values was determined with a Cochran-Armitage Trend Test. $p < 0.05$ was considered statistically significant. The SPSS software package (SPSS 11.0 for Windows; SPSS Inc., Chicago, Ill., USA) was used for analyses.

Results

Clinical Characteristics of the Patients

A total of 146 patients were enrolled in the present study. The clinical characteristics of patients before combination therapy are shown in table 1. In 15 patients, a liver biopsy was not available because the patients declined to have a biopsy taken. Reduction time after the initiation of combination therapy was 12.0 ± 12.7 weeks (mean \pm SD).

Predictors for SVR after Dose Reduction in Combination Therapy

Out of the 146 patients treated with dose reduction, 57 had SVR. Univariate analysis showed that the following seven factors significantly affected the SVR rate in all the patients: HCV RNA at the time of dose reduction ($p < 0.001$), HCV RNA at week 12 ($p < 0.001$), peginterferon

Table 1. Clinical characteristics before combination therapy of peginterferon and ribavirin in chronic hepatitis C patients (n = 146)

Characteristics	Patients, n or median (range)
Age, years	55 (20–69)
Male/female	81/65
Body weight, kg/height, cm	64.9 (36.7–96.6)/163.2 (135.2–185.5)
Body mass index	23.1 (16.6–32.0)
History of interferon therapy (-/+)	79/67
Liver histology (fibrosis, mild/moderate/severe)	61/47/23
HCV load, KIU/ml	1,500 (105–5,000)
AST/ALT, IU/l	55 (20–324)/76 (13–580)
Hemoglobin, g/dl	14.4 (10.4–17.9)
Platelets, $\times 10^4/\text{mm}^3$	14.1 (8.4–26.0)
WBC, $\times 10^3/\text{mm}^3$	4,200 (2,000–8,800)

ALT = Alanine aminotransferase; AST = aspartate aminotransferase; WBC = white blood cells.

and/or ribavirin dose ($p < 0.001$), sex ($p < 0.001$), HCV RNA level before treatment ($p = 0.024$), histopathological staging ($p = 0.031$), and HCV RNA at week 24 ($p = 0.042$) (table 2A). The variables were mutually correlated and multivariate Cox regression analysis was performed with the seven statistically significant variables in the model. As shown in table 2B, multivariate analysis showed that SVR occurred when serum HCV RNA at the time of dose reduction after the initiation of combination therapy was negative ($p < 0.001$) and total ribavirin dose was $\geq 100\%$ ($p < 0.001$).

SVR Rate Based on Adherence of Combination Therapy in Patients with Dose Reduction

The SVR rate based on adherence of combination therapy in patients with dose reduction was evaluated. Patients were divided into two groups based on the negativity or positivity of HCV RNA at the time of dose reduction after the initiation of combination therapy. Table 3A shows the SVR rate based on adherence of combination

Table 2. Predictive factors for SVR after dose reduction, based on combination therapy-related side effects

A Univariate analysis

Factor	Category	Odds ratio	95% CI	p value
HCV RNA at the time of reduction	-/+	1/0.09	0.04–0.21	<0.001
HCV RNA at week 12	-/+	1/0.09	0.04–0.22	<0.001
Total ribavirin dose, %	<100/ ≥ 100	1/8.58	3.99–18.47	<0.001
Total peginterferon dose, %	<100/ ≥ 100	1/3.37	1.672–7.04	<0.001
Sex	male/female	1/0.20	0.10–0.42	<0.001
HCV RNA, MEq/ml	<1,000/ $\geq 1,000$	1/0.43	0.21–0.90	0.024
Liver histology, fibrosis	mild/moderate or severe	1/0.46	0.23–0.93	0.031
HCV RNA at week 24	-/+	1/0.12	0.01–0.92	0.042
Hemoglobin, g/dl	<13/ ≥ 13	1/2.29	0.87–5.98	0.092
Platelets, $\times 10^4/\text{mm}^3$	<10/ ≥ 10	1/2.55	0.86–7.61	0.092
WBC, mm^3	<3,000/ $\geq 3,000$	1/1.14	0.40–1.27	0.062
ALT, IU/l	≥ 100 / < 100	1/1.31	0.59–2.93	0.164
Body mass index	<25/ ≥ 25	1/1.24	0.59–2.62	0.566
Age, years	<55/ ≥ 55	1/1.13	0.35–3.69	0.838

B Multivariate analysis

Factor	Category	Odds ratio	95% CI	p value
HCV RNA at the time of reduction	-/+	1/0.10	0.04–0.28	<0.001
Total ribavirin dose, %	<100/ ≥ 100	1/6.90	2.54–19.05	<0.001

ALT = Alanine aminotransferase; WBC = white blood cells.